Company intelligence / Profile preview

Genable Technologies

Dublin, Ireland

Ownership: Private
Development stage: Other

Overview

RhoNova™ demonstrated convincing preclinical data in animals for suppressing faulty rhodopsin gene and delivering normal RHO gene copies using AAV vectors; granted Orphan Drug Designation in US/EU and Advanced Therapy Medicinal Product designation in EU[1][2][3].

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Partnerships

Spark Therapeutics (pre-acquisition collaboration since 2014)

Beyond the preview

Go deeper on Genable Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genable Technologies.

Explore the full profile